See Enclomiphene dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Enclomiphene is the trans isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that antagonizes hypothalamic estrogen receptors to drive endogenous LH and FSH release without the agonist activity of the cis isomer (zuclomiphene). It is researched in the context of secondary hypogonadism in men and as a fertility-preserving alternative to exogenous testosterone replacement. This data captures the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with Enclomiphene.
Enclomiphene citrate is the pure trans (E) isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) developed by Repros Therapeutics under the brand name ANDROXAL as a deliberately purer alternative to the legacy clomiphene citrate (Clomid) preparation. Clomiphene as marketed has historically been a mixed isomer product — roughly 38% enclomiphene (the trans isomer, a pure estrogen-receptor antagonist with rapid clearance) and 62% zuclomiphene (the cis isomer, a long-half-life weak estrogen-receptor agonist). The therapeutic action in driving LH and FSH release through hypothalamic disinhibition comes almost entirely from the enclomiphene fraction; the zuclomiphene fraction provides little benefit and accumulates over weeks of dosing, and is the suspected source of the visual disturbances and mood side effects reported in chronic clomiphene use.
Enclomiphene is the trans-isomer of clomiphene, a non-steroidal selective estrogen receptor modulator (SERM) most often sourced for hormone-axis and fertility research. It was developed as Androxal for male secondary hypogonadism and completed Phase 3 trials, but the FDA never approved it. It is a small molecule (not a peptide), usually supplied as capsules or an oral liquid rather than a vial.
Enclomiphene blocks hypothalamic and pituitary estrogen receptors, removing the negative-feedback signal that estradiol normally provides to the hypothalamic-pituitary-gonadal (HPG) axis. The result is increased pulsatile GnRH release, which raises LH and FSH, which in turn raises endogenous testosterone production in men and stimulates ovulation in women. Unlike exogenous testosterone, enclomiphene preserves spermatogenesis and testicular size — the basis of its clinical appeal in men with secondary hypogonadism who want to preserve fertility.
5mg and 25mg daily restored serum total testosterone to the eugonadal range while preserving (or modestly increasing) sperm concentration, motility, and morphology — distinguishing it from exogenous testosterone, which suppresses spermatogenesis. The FDA's 2015 CRL focused on the design of the trials' primary endpoints (testosterone normalisation) rather than on safety, and Repros' subsequent attempt to recharacterise enclomiphene as a fertility-preserving alternative to testosterone replacement also did not reach approval.
Enclomiphene has a reported half-life of ~10 hours, and the dose intervals researchers model most often fall around once daily. Clears faster than regular clomiphene, so once-daily dosing keeps a steady level without the long lingering tail of the other isomer. It is catalogued under Other Peptides on WPA.
16 Enclomiphene reconstitution calculations have been logged by the WPA community. The most common dose entered is 7mcg (5 calculations). The median dose across all sessions is 100mcg. The most common bacteriostatic water volume is 300mL. The most popular vial size is 48mg (9 sessions). The most common dosing frequency is 4x/week (1 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.